Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Cardiff Oncology Inc

CRDF ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: HOLD

Last Close

$0.96

▼ -2.13%

Market Cap $74.92M · Vol 69.30K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$74.92M

Micro Cap

Div Yield

N/A

EPS Growth

+3.99%

YoY

RSI (14)

67.50

Momentum

Beta

1.46

vs Market

52W High

$3.31

70.86% below

52W Low

$0.76

26.71% above

Volume

69.30K

Avg 238.95K

P/B

4.23

Price-to-book

ROE

N/A

Return on equity

Free Float

93.81%

Public shares

Shariah Compliance8 STANDARDS

✗ Cardiff Oncology Inc (CRDF) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CRDF pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.91%

-26.49%

-44.34%

-39.81%

YTD

-65.73%

-60.53%

-51.85%

-83.22%

Financials & Valuation

TTM · Annual

Total Revenue	$593.00K
Net Income	$-45,851,000.00
Revenue Growth (YoY)	-14.05%
Gross Margin	100.00%
Operating Margin	-8,256.32%
Net Profit Margin	-7,732.04%
ROE	N/A
ROA · ROIC	-57.65% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	316.73
P/B	4.23
P/FCF	N/A
EPS Growth	+3.99%
Outstanding Shares	77.80M

Technical Indicators

50-Day SMA	$1.14
200-Day SMA	$1.81
RSI (14)	67.50
Beta	1.46
52-Week High	$3.31
52-Week Low	$0.76

Volume Today	69.30K
Avg Daily Volume (30D)	238.95K
Relative Volume	0.29x
Volatility (10D)	58.94
Volatility (30D)	123.16
Free Float	93.81%

Analyst Consensus

HOLD

Current Price $0.96

Mean Target $7.50

52W Low$0.76 52W High$3.31

Current

Target

$0.76 $3.31

Current Analyst target

+678.82% upside potential · 9 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SLWWP7

ISINUS14147L1089

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 6, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Cardiff Oncology, Inc. is a clinical-stage biotechnology company advancing cancer treatments focused on Polo-like Kinase 1 (PLK1) inhibition, a validated oncology target with practice-changing potential. The Company's lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor being evaluated in a Phase II trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic myelomonocytic leukemia (CMML). The Company's clinical development programs incorporate tumor genomics and biomarker assays to refine patient selection and assessment of patient response to treatment.